
Provisional Authorisation for COVID-19 Tests

<i>Applicant</i>	Abbott Laboratories (Singapore) Pte Ltd
<i>Name of test</i>	Abbott Alinity m SARS-CoV-2 AMP Kit
<i>Intended purpose (As per manufacturer's information for use)</i>	<p><i>The Alinity m SARS-CoV-2 assay is a real-time (rt) reverse transcriptase (RT) polymerase chain reaction (PCR) test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal (NP) and oropharyngeal (OP) swabs collected by a healthcare provider, from patients who are suspected of COVID-19 infection.</i></p> <p><i>Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in nasopharyngeal and oropharyngeal swabs during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses.</i></p> <p><i>Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.</i></p> <p><i>The Alinity m SARS-CoV-2 assay is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures.</i></p>
<i>Date of Provisional Authorisation</i>	14 September 2020
